Piracetam

Different receptor profiles complement each other

Broader cognitive enhancement

⟡ Choline

Racetams may increase acetylcholine demand

Prevents headaches from racetam use; enhanced cognitive effects

⟡ Noopept

Different mechanisms complement each other

Synergistic cognitive enhancement

⟡ Oxiracetam

Different receptor profiles

Broader nootropic effects

Top studies from 38+ peer-reviewed papers

📚meta-analysisn=1002

Ricci S et al. • The Cochrane database of systematic reviews (2012)

“There is some suggestion (but no statistically significant result) of an unfavourable effect of piracetam on early death, but this may have been caused by baseline differences in stroke severity in the trials.”

Key Findings:

We included three trials involving 1002 patients, with one trial contributing 93% of the data.
Piracetam was associated with a statistically non-significant increase in death at one month (approximately 31% increase, 95% confidence interval 81% increase to 5% reduction).
There is some suggestion (but no statistically significant result) of an unfavourable effect of piracetam on early death, but this may have been caused by baseline differences in stroke severity in the trials.
There is not enough evidence to assess the effect of piracetam on dependence.

📚meta-analysisn=12339

Liang CW et al. • Progress in neuro-psychopharmacology & biological psychiatry (2025)

“Notably, memantine, N-acetylcysteine, and sarcosine exhibited efficacy across multiple outcome domains.”

Key Findings:

Notably, memantine, N-acetylcysteine, and sarcosine exhibited efficacy across multiple outcome domains.
The effects of some novel agents within specific dose ranges on cognitive function improvement were also observed.

📚meta-analysisn=1387

Verdijk JPAJ et al. • Acta psychiatrica Scandinavica (2022)

“Memantine and liothyronine are promising for further research and future application.”

Key Findings:

Low-quality evidence of efficacy was established for memantine (large effect size) and liothyronine (medium effect size).
Memantine and liothyronine are promising for further research and future application.
Quality of evidence was low because of differences in ECT techniques, study populations and cognitive measurements.
These findings provide a guide for rational choices of potential pharmacological intervention research targets to decrease the burden of cognitive side effects of ECT.

📚meta-analysisn=44854

Perng CH et al. • Psychopharmacology (2018)

“The most effective intervention for dementia available is symptomatic treatment for vascular dementia.”

Key Findings:

The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
The most effective intervention for dementia available is symptomatic treatment for vascular dementia.
Antipsychotic treatment for dementia alleviates cognitive dysfunction less effectively than does symptomatic treatment.
Alternative therapies are also effective at present.

📚systematic-review

Compare with Others Find Based on Your Goals

Nistor M et al. • International journal of molecular sciences (2017)

“This important topic therefore requires more in-depth research.”

Key Findings:

We identified three subsets of results: (1) hypothermia; (2) fluid therapy and/or vasopressors; and (3) other neuroprotective strategies (piracetam, NHE1-inhibition, aprotinin, human mesenchymal stem cells, remote ischemic preconditioning and sevoflurane).
Overall, risk of bias according to SYRCLE's tool was medium; generally, animal experimental models require more rigorous adherence to the reporting of bias-free study design (randomization, etc.).
While the individual study results are promising, the retrieved neuroprotective strategies have to be evaluated within the current scientific context-by doing so, it becomes clear that specific promising neuroprotective strategies during states of haemorrhagic shock remain sparse.
This important topic therefore requires more in-depth research.

View all 38+ studies

What would you like to do next?

Related Supplements

Hu7.5

Huperzine A

7.5/10

Inhibits acetylcholinesterase to raise acetylcholine levels, enhancing memory formation, focus, and learning capacity.

Np5.5

Noopept

5.5/10

Synthetic peptide ~1,000x more potent than piracetam that boosts NGF and BDNF for memory, learning, and neuroprotection.

Agp8.5

Alpha-GPC

Crosses the blood-brain barrier to fuel acetylcholine synthesis — supports focus, memory, and power output in athletes.

Cit8.5

Citicoline

Dual precursor to acetylcholine and phosphatidylcholine — enhances memory, focus, and brain cell membrane repair.

Pm9.0

Piracetam

compound

Piracetam

First-ever nootropic (1972) that improves membrane fluidity and AMPA receptor function — decades of safety data for cognitive enhancement.

mentalnootropiccognitivememorylearning

38+ studies

Evidence

Reviewed 19 days ago

high

Safety

1200-4800mg daily in divided doses

Dose

4-12 weeks

Time to Effect

Piracetam powder or capsules

Best Form

Mechanisms of Action

⚡

AMPA Receptor Modulation

Positive allosteric modulator of AMPA receptors

🔄

Membrane Fluidity

Improves neuronal membrane flexibility

🧠

Cholinergic Enhancement

Increases acetylcholine activity

Biological PathwayBeta

How Piracetam works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.

Supplement

Molecular Target

Biological Process

Health Outcome

Strong

Moderate

Emerging

strong

moderate

emerging

Tap node to isolate • Pinch to zoom • Tap edge for research

Recommended Dose

1200-4800mg daily in divided doses

800mg4800mg

Loading: Some use 2-3x normal dose for first few days; not required

Optimal Timing

Divided into 2-3 doses
Morning and early afternoon
With a choline source

Can be taken without food

Available Forms

Form	Type
💊Piracetam powder or capsules	Recommended

Available as powder (economical) or capsules. Bulk powder requires accurate dosing scale.

Duration

Minimum: 4 weeks

Optimal: 12 weeks

Cycling: 8-12 weeks on, 2-4 weeks off; or continuous use is reported safe by many

Note: Water-soluble and well-absorbed. Combining with Alpha-GPC or CDP-Choline prevents headaches and enhances effects.

💡

Memory Enhancement

Improved verbal memory and learning

⏱️ 2-4 weeks

65% of users notice thispositive

🎯

Cognitive Clarity

Clearer thinking and mental processing

⏱️ 1-2 weeks

60% of users notice thispositive

🛡️

Neuroprotection

Protection against cognitive decline

📅 Ongoing

55% of users notice thispositive

🤕

Headache (if low choline)

Can cause headaches without adequate choline

⚡ First few days

25% of users notice thistrade-off

High SafetyMax safe dose: 4800mg/day commonly used; higher doses studied

🟡

Elderly with cognitive decline

Well-studied population; may see greatest benefits

Who Should NOT Take This

Severe kidney impairment (excreted renally)
Huntington's disease (theoretical concern)

Drug Interactions

Blood thinnersmild

May slightly enhance anticoagulant effects

Possible Side Effects

Headache

mildcommon

Tip: Take with choline source (Alpha-GPC, CDP-Choline)

Insomnia

milduncommon

Tip: Avoid evening doses

Warnings

Not FDA-approved in US (sold as supplement/research compound)
Combine with choline to prevent headaches
Regulatory status varies by country

✦ Alpha-GPC

enhances

Provides choline for enhanced effects

Stronger cognitive benefits, prevents headaches

⟡ Aniracetam

Different receptor profiles complement each other

Broader cognitive enhancement

⟡ Choline

Racetams may increase acetylcholine demand

Prevents headaches from racetam use; enhanced cognitive effects

⟡ Noopept

Different mechanisms complement each other

Synergistic cognitive enhancement

⟡ Oxiracetam

Different receptor profiles

Broader nootropic effects

Top studies from 38+ peer-reviewed papers

📚meta-analysisn=1002

Ricci S et al. • The Cochrane database of systematic reviews (2012)

“There is some suggestion (but no statistically significant result) of an unfavourable effect of piracetam on early death, but this may have been caused by baseline differences in stroke severity in the trials.”

Key Findings:

We included three trials involving 1002 patients, with one trial contributing 93% of the data.
Piracetam was associated with a statistically non-significant increase in death at one month (approximately 31% increase, 95% confidence interval 81% increase to 5% reduction).
There is some suggestion (but no statistically significant result) of an unfavourable effect of piracetam on early death, but this may have been caused by baseline differences in stroke severity in the trials.
There is not enough evidence to assess the effect of piracetam on dependence.

📚meta-analysisn=12339

Liang CW et al. • Progress in neuro-psychopharmacology & biological psychiatry (2025)

“Notably, memantine, N-acetylcysteine, and sarcosine exhibited efficacy across multiple outcome domains.”

Key Findings:

Notably, memantine, N-acetylcysteine, and sarcosine exhibited efficacy across multiple outcome domains.
The effects of some novel agents within specific dose ranges on cognitive function improvement were also observed.

📚meta-analysisn=1387

Verdijk JPAJ et al. • Acta psychiatrica Scandinavica (2022)

“Memantine and liothyronine are promising for further research and future application.”

Key Findings:

Low-quality evidence of efficacy was established for memantine (large effect size) and liothyronine (medium effect size).
Memantine and liothyronine are promising for further research and future application.
Quality of evidence was low because of differences in ECT techniques, study populations and cognitive measurements.
These findings provide a guide for rational choices of potential pharmacological intervention research targets to decrease the burden of cognitive side effects of ECT.

📚meta-analysisn=44854

Perng CH et al. • Psychopharmacology (2018)

“The most effective intervention for dementia available is symptomatic treatment for vascular dementia.”

Key Findings:

The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
The most effective intervention for dementia available is symptomatic treatment for vascular dementia.
Antipsychotic treatment for dementia alleviates cognitive dysfunction less effectively than does symptomatic treatment.
Alternative therapies are also effective at present.

📚systematic-review

Compare with Others Find Based on Your Goals

Nistor M et al. • International journal of molecular sciences (2017)

“This important topic therefore requires more in-depth research.”

Key Findings:

We identified three subsets of results: (1) hypothermia; (2) fluid therapy and/or vasopressors; and (3) other neuroprotective strategies (piracetam, NHE1-inhibition, aprotinin, human mesenchymal stem cells, remote ischemic preconditioning and sevoflurane).
Overall, risk of bias according to SYRCLE's tool was medium; generally, animal experimental models require more rigorous adherence to the reporting of bias-free study design (randomization, etc.).
While the individual study results are promising, the retrieved neuroprotective strategies have to be evaluated within the current scientific context-by doing so, it becomes clear that specific promising neuroprotective strategies during states of haemorrhagic shock remain sparse.
This important topic therefore requires more in-depth research.

View all 38+ studies

What would you like to do next?

Related Supplements

Hu7.5

Huperzine A

7.5/10

Inhibits acetylcholinesterase to raise acetylcholine levels, enhancing memory formation, focus, and learning capacity.

Np5.5

Noopept

5.5/10

Synthetic peptide ~1,000x more potent than piracetam that boosts NGF and BDNF for memory, learning, and neuroprotection.

Agp8.5

Alpha-GPC

Crosses the blood-brain barrier to fuel acetylcholine synthesis — supports focus, memory, and power output in athletes.

Cit8.5

Citicoline